Proxy Votes Now

Home › Funds › Fidelity › Fidelity MSCI Health Care Index ETF

Fidelity MSCI Health Care Index ETF (FHLC) proxy voting record 2025-2026

Fund family: Fidelity · Filed by FIDELITY COVINGTON TRUST (CIK 945908) · SEC series S000042575

Ticker: FHLC (C000131667)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 2,773 with, 47 against, 0 abstentions (not counted as with management); 3 items carried no recommendation. Shareholder proposals: 1 FOR, 37 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Fidelity as a whole

The same two figures as Fidelity’s manager page (1,165,189 ballot items across 406 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsFidelityItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)95.8%2,69894.1%974,562
Backed environmental and social shareholder proposals at US companiesn/a96.8%11,096

Where this fund voted differently from most Fidelity funds

Each ballot item this fund voted is set against the votes of the other Fidelity funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Fidelity funds on 122 items (4.4% of the 2,751 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Fidelity fundsMgmtResult
Moderna, Inc.2026-05-06To elect two Class II director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her other respective successor is duly elected and qualified or such director's earlier death, resignation or removal: SaAgainstFOR — 73 of 73 Fidelity fundsAgainstElected, 81.0% support
Doximity, Inc.2025-08-28To approve, on a non-binding advisory basis, the compensation paid to the Company's named executive officers for the fiscal year ended March 31, 2025.AgainstFOR — 57 of 57 Fidelity fundsAgainstPassed (calculated), 96.4% support
Viking Therapeutics, Inc.2026-05-19TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.AgainstFOR — 46 of 46 Fidelity fundsAgainstApproved, 70.2% support
Humana Inc.2026-04-16Election of Directors: Wayne A. I. Frederick, M.D.AgainstFOR — 41 of 41 Fidelity fundsAgainstElected, 83.4% support
Incyte Corporation2026-06-08Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.AgainstFOR — 39 of 39 Fidelity fundsAgainstApproved, 83.9% support
LifeStance Health Group, Inc.2026-06-02Election of two director nominees named in the Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Robert Bessler, M.D.WithholdFOR — 39 of 39 Fidelity fundsAgainstElected, 85.1% support
Travere Therapeutics, Inc.2026-05-19To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Roy BaynesWithholdFOR — 38 of 38 Fidelity fundsAgainstElected, 87.7% support
Incyte Corporation2026-06-08Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Jean-Jacques BienaimeAgainstFOR — 35 of 35 Fidelity fundsAgainstElected, 84.2% support
Mirum Pharmaceuticals, Inc.2026-06-15To elect the Board's three Class III nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Timothy WalbertWithholdFOR — 33 of 33 Fidelity fundsAgainstElected, 69.7% support
Scholar Rock Holding Corporation2026-06-04To elect four Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Kristina BurowWithholdFOR — 36 of 36 Fidelity fundsAgainstElected, 81.6% support
Scholar Rock Holding Corporation2026-06-04To elect four Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Michael GilmanWithholdFOR — 36 of 36 Fidelity fundsAgainstElected, 78.2% support
Apogee Therapeutics, Inc.2026-06-09Election of Class III Directors for terms expiring in 2029: William (BJ) Jones, Jr.WithholdFOR — 34 of 34 Fidelity fundsAgainstPassed (calculated), 81.5% support
Penumbra, Inc.2026-06-18To elect the nominees for Class II director to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Arani Bose, M.D.WithholdFOR — 29 of 29 Fidelity fundsAgainstElected, 84.9% support
Henry Schein, Inc.2026-05-21Shareholder Proposal to approve, by non-binding vote, a shareholder proposal to Govern by Majority Vote.AgainstFOR — 29 of 29 Fidelity fundsForApproved, 57.6% support
Universal Health Services, Inc.2026-05-20Shareholder Stockholder proposal to report votes based on UHS shareholder money at risk, if properly presented at the meeting.AgainstFOR — 26 of 26 Fidelity fundsForFailed (calculated), 4.7% support
Acadia Healthcare Company, Inc.2026-05-06Election of Directors: Michael J. FucciAgainstFOR — 24 of 24 Fidelity fundsAgainstElected, 91.0% support
MBX Biosciences, Inc.2026-06-04Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Edward T. MathersWithholdFOR — 24 of 24 Fidelity fundsAgainstPassed (calculated), 80.8% support
Alumis Inc.2026-06-30To elect the three Class II director nominees named below to serve until the Company's 2029 annual meeting of stockholders: Zhengbin (Bing) Yao, Ph.D.WithholdFOR — 24 of 24 Fidelity fundsAgainstPassed (calculated), 84.1% support
Labcorp Holdings Inc.2026-05-21Election of the members of the Company's Board of Directors: Garheng Kong, M.D., Ph.D.AgainstFOR — 21 of 21 Fidelity fundsAgainstElected, 71.4% support
Denali Therapeutics Inc.2026-06-03ELECTION OF DIRECTORS: Jennifer CookWithholdFOR — 21 of 21 Fidelity fundsAgainstElected, 60.9% support
Harmony Biosciences Holdings, Inc.2026-05-14The election of four Class III directors to serve until our 2029 annual meeting of stockholders and until their successors are duly elected and qualified. Andreas Wicki, Ph.D.WithholdFOR — 21 of 21 Fidelity fundsAgainstElected, 54.0% support
Harmony Biosciences Holdings, Inc.2026-05-14The election of four Class III directors to serve until our 2029 annual meeting of stockholders and until their successors are duly elected and qualified. Troy IgnelziWithholdFOR — 22 of 22 Fidelity fundsAgainstElected, 70.6% support
Acadia Pharmaceuticals Inc.2026-05-29To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Edmund P. Harrigan, M.D.WithholdFOR — 19 of 19 Fidelity fundsAgainstPassed (calculated), 85.4% support
Sarepta Therapeutics, Inc.2026-06-04To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified or their earlier death, resignation or removal, the following director nominees: Deirdre ConnellyAgainstFOR — 19 of 19 Fidelity fundsAgainstElected, 79.0% support
Ocular Therapeutix, Inc.2026-06-10To approve an advisory vote on named executive officer compensation.AgainstFOR — 28 of 29 Fidelity fundsAgainst—
Show all 122
Items 26 to 122.
CompanyMeetingItemThis fundMost Fidelity fundsMgmtResult
Aveanna Healthcare Holdings Inc.2026-05-29To approve, on an advisory, non-binding, basis, the compensation paid to the Company's Named Executive Officers identified in the accompanying Proxy Statement.AgainstFOR — 18 of 18 Fidelity fundsAgainstPassed (calculated), 89.1% support
Aveanna Healthcare Holdings Inc.2026-05-29To elect the three Class II director nominees identified in the accompanying Proxy Statement to the Board of Directors of the Company, each to serve a three-year term expiring at the 2029 Annual Meeting of the Company's stockholders: Steven E. RodgersWithholdFOR — 17 of 17 Fidelity fundsAgainstPassed (calculated), 93.7% support
NewAmsterdam Pharma Company N.V.2026-06-02Extension of authorization for the Board of Directors to issue ordinary shares (or rights to subscribe for ordinary shares) in the Company's capital.AgainstFOR — 26 of 27 Fidelity fundsAgainstApproved, 69.0% support
NovoCure Limited2026-06-03The approval of our amended and restated 2024 Omnibus Incentive Plan.ForAGAINST — 18 of 18 Fidelity fundsForApproved, 50.3% support
STAAR Surgical Company2026-01-06A proposal to approve, on an advisory (nonbinding) basis, the compensation that may be paid or become payable to STAAR's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement.AgainstFOR — 17 of 17 Fidelity fundsAgainstNot approved, 33.8% support
Alphatec Holdings, Inc.2026-06-10To elect seven persons to our Board of Directors: Quentin BlackfordWithholdFOR — 17 of 17 Fidelity fundsAgainstPassed (calculated), 71.1% support
IRadimed Corporation2026-06-23Election of Directors: Monty AllenWithholdFOR — 18 of 18 Fidelity fundsAgainstElected, 87.3% support
Sana Biotechnology, Inc.2026-06-04To elect three Class II directors to our Board of Directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: Alise S. Reicin, M.D.WithholdFOR — 17 of 17 Fidelity fundsAgainst—
CorVel Corporation2025-08-07To elect six directors, each to serve until the annual meeting of stockholders to be held in 2026 or until his or her successor has been duly elected and qualified: R. Judd JessupWithholdFOR — 16 of 16 Fidelity fundsAgainstPassed (calculated), 87.6% support
Celcuity Inc.2026-05-14To approve, on an advisory basis, named executive officer compensation.ForAGAINST — 16 of 16 Fidelity fundsForPassed (calculated), 95.1% support
LeMaitre Vascular, Inc.2026-06-02Election of Directors: John A. RoushWithholdFOR — 16 of 16 Fidelity fundsAgainst—
Bio-Rad Laboratories, Inc.2026-04-21Nominees: Arnold A. PinkstonForAGAINST — 15 of 15 Fidelity fundsForPassed (calculated), 88.8% support
Bio-Rad Laboratories, Inc.2026-04-21Nominees: Melinda LitherlandForAGAINST — 15 of 15 Fidelity fundsForPassed (calculated), 88.3% support
CorVel Corporation2025-08-07To elect six directors, each to serve until the annual meeting of stockholders to be held in 2026 or until his or her successor has been duly elected and qualified: Jeffrey J. MichaelWithholdFOR — 15 of 15 Fidelity fundsAgainstPassed (calculated), 84.4% support
Celcuity Inc.2026-05-14To approve the Celcuity Inc. Amended and Restated Employee Stock Purchase Plan.AgainstFOR — 15 of 15 Fidelity fundsAgainst—
Agios Pharmaceuticals, Inc.2026-06-18To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Cynthia SmithWithholdFOR — 15 of 15 Fidelity fundsAgainstPassed (calculated), 68.3% support
Wave Life Sciences Ltd.2025-08-05The election of the nominees for director: Christian HenryAgainstFOR — 15 of 15 Fidelity fundsAgainstPassed (calculated), 85.4% support
ImmunityBio, Inc.2026-06-09Election of Directors: Linda Maxwell, M.D.WithholdFOR — 14 of 14 Fidelity fundsAgainstElected, 97.9% support
Guardian Pharmacy Services, Inc.2026-05-05To elect Class II directors, to hold office until the annual meeting of stockholders to be held in 2029 and until their successors are duly elected and qualified: John AckermanForWITHHOLD — 14 of 14 Fidelity fundsForElected, 82.3% support
Guardian Pharmacy Services, Inc.2026-05-05To elect Class II directors, to hold office until the annual meeting of stockholders to be held in 2029 and until their successors are duly elected and qualified: Randall LewisWithholdFOR — 14 of 14 Fidelity fundsAgainstElected, 82.6% support
Perrigo Company plc2026-04-30To elect, by separate resolutions, nine director nominees to serve until the 2027 Annual General Meeting of Shareholders: Albert A. ManzoneAgainstFOR — 14 of 14 Fidelity fundsAgainstPassed (calculated), 85.9% support
Azenta, Inc.2026-01-28Election of Directors: Tina S. NovaWithholdFOR — 14 of 14 Fidelity fundsAgainstElected, 82.2% support
Phibro Animal Health Corporation2025-11-04Election of Class III Directors: E. Thomas CorcoranWithholdFOR — 21 of 22 Fidelity fundsAgainstElected, 96.0% support
STAAR Surgical Company2026-01-06A proposal to adopt the Agreement and Plan of Merger, dated as of August 4, 2025, as may be amended from time to time (the "Merger Agreement"), by and among STAAR Surgical Company ("STAAR"), Alcon Research, LLC, a Delaware limited liability company ("Alcon"), and Rascasse Merger Sub, Inc., a DelawarAgainstFOR — 14 of 14 Fidelity fundsAgainstNot approved, 35.3% support
Arbutus Biopharma Corporation2026-05-26To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual General and Special Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Matthew GlineWithholdFOR — 14 of 14 Fidelity fundsAgainstPassed (calculated), 86.5% support
ARS Pharmaceuticals, Inc.2026-06-24To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Phillip SchneiderWithholdFOR — 14 of 14 Fidelity fundsAgainstElected, 58.3% support
Palvella Therapeutics, Inc.2026-06-10Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5.ForAGAINST — 13 of 13 Fidelity fundsForPassed (calculated), 75.2% support
Palvella Therapeutics, Inc.2026-06-10Approval of an amendment to the 2024 Equity Incentive Plan to increase the authorized shares issuable under the 2024 Plan by 750,000 shares.ForAGAINST — 13 of 13 Fidelity fundsFor—
Avidity Biosciences, Inc.2026-02-26To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to our named executive officers in connection with the transactions contemplated by the Merger Agreement and the Separation Agreement.AgainstFOR — 20 of 21 Fidelity fundsAgainstApproved, 82.4% support
Taysha Gene Therapies, Inc.2026-06-01To elect the Board's Class III Director nominees, Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Laura Sepp-Lorenzino, Ph.D.WithholdFOR — 19 of 20 Fidelity fundsAgainstElected, 73.3% support
OPKO Health, Inc.2026-06-18To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: John A. PaganelliForAGAINST — 12 of 12 Fidelity fundsForElected, 85.8% support
OPKO Health, Inc.2026-06-18To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: Steven D. RubinForAGAINST — 12 of 12 Fidelity fundsForElected, 88.2% support
Merus N.V.2025-12-09Appointment of Anthony Pagano as non-executive director of MerusForAGAINST — 12 of 12 Fidelity fundsFor—
Merus N.V.2025-12-09Appointment of Greg Mueller as non-executive director of MerusForAGAINST — 12 of 12 Fidelity fundsFor—
Merus N.V.2025-12-09Appointment of Martine van Vugt, Ph.D., as non-executive director of MerusForAGAINST — 12 of 12 Fidelity fundsFor—
SI-BONE, Inc.2026-06-04Election of Directors: Jeffrey W. DunnWithholdFOR — 11 of 11 Fidelity fundsAgainstElected, 63.4% support
Ginkgo Bioworks Holdings, Inc.2026-06-11Election of Directors: Christian HenryAgainstFOR — 11 of 11 Fidelity fundsAgainstElected, 87.1% support
Ginkgo Bioworks Holdings, Inc.2026-06-11Election of Directors: Harry E. SloanForAGAINST — 11 of 11 Fidelity fundsForElected, 90.0% support
Ginkgo Bioworks Holdings, Inc.2026-06-11Election of Directors: Ross FubiniForAGAINST — 11 of 11 Fidelity fundsForElected, 92.6% support
CorMedix Inc.2026-06-23Election of Directors: Myron KaplanWithholdFOR — 11 of 11 Fidelity fundsAgainstElected, 87.4% support
Tempus AI, Inc.2026-05-21To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Wayne A.I. Frederick, M.D.WithholdFOR — 10 of 10 Fidelity fundsAgainstPassed (calculated), 99.3% support
NewAmsterdam Pharma Company N.V.2026-06-02Extension of authorization for the Board of Directors to limit or exclude pre-emption rights.AgainstFOR — 24 of 27 Fidelity fundsAgainstApproved, 67.0% support
UroGen Pharma Ltd.2026-06-22To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Arie Belldegrun, M.D.AgainstFOR — 9 of 9 Fidelity fundsAgainstElected, 82.5% support
GoodRx Holdings, Inc.2026-06-16Election of Directors: Gregory MondreWithholdFOR — 9 of 9 Fidelity fundsAgainstPassed (calculated), 99.7% support
Ardelyx, Inc.2026-06-16To approve the amendment to the Amended and Restated 2014 Equity Incentive Award Plan, or the Restated Plan, to increase the maximum number of shares of common stock that may be delivered pursuant to awards granted under the Restated Plan by 9,000,000 shares.ForAGAINST — 14 of 15 Fidelity fundsForApproved, 52.6% support
Inhibrx Biosciences, Inc.2026-06-03To elect two Class II directors, nominated by our Board of Directors, to serve until our 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their respective earlier death, resignation, or removal: Douglas G. ForsythWithholdFOR — 9 of 9 Fidelity fundsAgainst—
ARS Pharmaceuticals, Inc.2026-06-24To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Laura Shawver, Ph.D.WithholdFOR — 13 of 14 Fidelity fundsAgainstElected, 68.4% support
Hims & Hers Health, Inc.2026-06-11Election of Directors: Andrew DudumForWITHHOLD — 12 of 13 Fidelity fundsForPassed (calculated), 99.1% support
Pulse Biosciences, Inc.2026-06-11Election of Directors: Manmeet S. SoniAgainstFOR — 12 of 13 Fidelity fundsAgainstElected, 95.8% support
Clover Health Investments, Corp.2026-06-10ELECTION OF DIRECTORS: Thomas L. TranForWITHHOLD — 12 of 13 Fidelity fundsForElected, 98.3% support
Fulgent Genetics, Inc.2026-05-14Election of Directors: Linda DongWithholdFOR — 12 of 13 Fidelity fundsAgainstPassed (calculated), 75.7% support
Fulgent Genetics, Inc.2026-05-14Election of Directors: Regina GrovesWithholdFOR — 12 of 13 Fidelity fundsAgainstPassed (calculated), 73.0% support
Standard BioTools Inc.2026-06-17To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement.ForAGAINST — 12 of 13 Fidelity fundsForApproved, 85.2% support
ARS Pharmaceuticals, Inc.2026-06-24To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.ForAGAINST — 15 of 17 Fidelity fundsForApproved, 87.6% support
CRISPR Therapeutics AG2026-06-04Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securities law requirements.ForAGAINST — 7 of 7 Fidelity fundsForApproved, 69.4% support
Universal Health Services, Inc.2026-05-20Election of Director: Nina Chen-LangenmayrForWITHHOLD — 20 of 24 Fidelity fundsFor—
Celcuity Inc.2026-05-14Elect eight directors: Leo T. FurchtWithholdFOR — 13 of 15 Fidelity fundsAgainstPassed (calculated), 85.0% support
Ardent Health, Inc.2026-05-20Election of Directors: Peter BynoeWithholdFOR — 6 of 6 Fidelity fundsAgainstPassed (calculated), 95.2% support
IRadimed Corporation2026-06-23Election of Directors: James HawkinsForWITHHOLD — 15 of 18 Fidelity fundsForElected, 77.7% support
IRadimed Corporation2026-06-23Election of Directors: Roger SusiForWITHHOLD — 15 of 18 Fidelity fundsForElected, 81.4% support
Tempus AI, Inc.2026-05-21To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Theodore J. LeonsisForWITHHOLD — 9 of 10 Fidelity fundsForPassed (calculated), 94.4% support
Aveanna Healthcare Holdings Inc.2026-05-29To elect the three Class II director nominees identified in the accompanying Proxy Statement to the Board of Directors of the Company, each to serve a three-year term expiring at the 2029 Annual Meeting of the Company's stockholders: Rodney D. WindleyWithholdFOR — 14 of 17 Fidelity fundsAgainstPassed (calculated), 83.5% support
HealthStream, Inc.2026-05-28To elect three Class II directors (A. Alex Jahangir, Jeffrey L. McLaren, and Linda E. Rebrovick) to hold office for a term of three (3) years and until their successors have been duly elected and qualified: Jeffrey L. McLarenWithholdFOR — 14 of 17 Fidelity fundsAgainstElected, 58.2% support
CRISPR Therapeutics AG2026-06-04Binding vote on maximum equity for members of the Executive Committee from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.ForAGAINST — 5 of 5 Fidelity fundsFor—
CRISPR Therapeutics AG2026-06-04Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2026 to June 30, 2027.ForAGAINST — 5 of 5 Fidelity fundsFor—
CRISPR Therapeutics AG2026-06-04Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2026.ForAGAINST — 5 of 5 Fidelity fundsFor—
CRISPR Therapeutics AG2026-06-04Non-binding advisory vote on the 2025 Compensation Report.ForAGAINST — 5 of 5 Fidelity fundsFor—
CRISPR Therapeutics AG2026-06-04Re-election of Briggs W. Morrison, M.D.ForAGAINST — 5 of 5 Fidelity fundsFor—
CRISPR Therapeutics AG2026-06-04Re-election of Douglas A. Treco, Ph.D.AgainstFOR — 5 of 5 Fidelity fundsAgainstElected, 91.1% support
CRISPR Therapeutics AG2026-06-04Re-election of H. Edward Fleming, Jr., M.D.ForAGAINST — 5 of 5 Fidelity fundsFor—
CRISPR Therapeutics AG2026-06-04Re-election of John T. GreeneForAGAINST — 5 of 5 Fidelity fundsFor—
Merus N.V.2025-12-09Appointment of Anthony Pagano as non-executive director of Merus Opportunity for Merus Shareholders to make recommendations at the EGM to Merus' non-executive directors in respect of their nomination to appoint a non-executive directorForAGAINST — 10 of 12 Fidelity funds—Passed (calculated), 78.5% support
Merus N.V.2025-12-09Appointment of Greg Mueller as non-executive director of Merus Opportunity for Merus Shareholders to make recommendations at the EGM to Merus' non-executive directors in respect of their nomination to appoint a non-executive directorForAGAINST — 10 of 12 Fidelity funds—Passed (calculated), 78.5% support
Merus N.V.2025-12-09Appointment of Martine van Vugt, Ph.D., as non-executive director of Merus Opportunity for Merus Shareholders to make recommendations at the EGM to Merus' non-executive directors in respect of their nomination to appoint a non-executive directorForAGAINST — 10 of 12 Fidelity funds—Passed (calculated), 78.5% support
Natera, Inc.2026-06-11To approve an amendment to Natera's 2015 Equity Incentive Plan, as amended and restated.ForAGAINST — 31 of 45 Fidelity fundsForPassed (calculated), 78.1% support
TG Therapeutics, Inc.2026-06-11Election of Directors: Sagar Lonial, MDWithholdFOR — 13 of 17 Fidelity fundsAgainstPassed (calculated), 54.9% support
Edgewise Therapeutics, Inc.2026-06-04Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Badreddin Edris, Ph.D.WithholdFOR — 13 of 17 Fidelity fundsAgainstElected, 70.3% support
Edgewise Therapeutics, Inc.2026-06-04Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Jonathan Root, M.D.WithholdFOR — 13 of 17 Fidelity fundsAgainstElected, 65.0% support
Xeris Biopharma Holdings, Inc.2026-06-04To elect two Class II directors to our board of directors to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: John JohnsonWithholdFOR — 13 of 17 Fidelity fundsAgainstElected, 60.2% support
Capricor Therapeutics, Inc.2026-06-04ELECTION OF DIRECTORS: Frank LitvackWithholdFOR — 13 of 17 Fidelity fundsAgainstPassed (calculated), 68.6% support
Sana Biotechnology, Inc.2026-06-04To elect three Class II directors to our Board of Directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: Hans E. BishopWithholdFOR — 13 of 17 Fidelity fundsAgainst—
Doximity, Inc.2025-08-28To elect two Class I Directors to serve until the annual meeting of stockholders to be held in 2028 or until their successors are duly elected and qualified: Kira WamplerWithholdFOR — 33 of 52 Fidelity fundsAgainstElected, 91.7% support
Scholar Rock Holding Corporation2026-06-04To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.AgainstFOR — 26 of 40 Fidelity fundsAgainstApproved, 61.7% support
Henry Schein, Inc.2026-05-21Election of Incumbent Directors: Max LinAgainstFOR — 18 of 27 Fidelity fundsAgainstPassed (calculated), 77.3% support
LifeStance Health Group, Inc.2026-06-02Election of two director nominees named in the Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: David BourdonForWITHHOLD — 25 of 39 Fidelity fundsForElected, 74.5% support
Nuvation Bio Inc.2026-05-21Election of Directors: Robert BazemoreForWITHHOLD — 12 of 17 Fidelity fundsForElected, 84.0% support
Stryker Corporation2026-05-06Election Directors: Emmanuel P. MacedaForAGAINST — 22 of 36 Fidelity fundsForElected, 81.9% support
Stryker Corporation2026-05-06Election Directors: Ronda E. StrykerForAGAINST — 22 of 37 Fidelity fundsForElected, 96.6% support
Progyny, Inc.2026-05-21Election of Directors: Cheryl ScottForWITHHOLD — 14 of 23 Fidelity fundsForElected, 76.2% support
Arrowhead Pharmaceuticals, Inc.2026-03-19Election of Directors: Michael S. PerryAgainstFOR — 13 of 22 Fidelity fundsAgainst—
Immunovant, Inc.2025-08-27To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Douglas HughesWithholdFOR — 16 of 28 Fidelity fundsAgainstElected, 89.5% support
Stoke Therapeutics, Inc.2026-06-03To approve, on an advisory basis, the compensation of the Company's named executive officers.ForAGAINST — 17 of 30 Fidelity fundsForPassed (calculated), 72.9% support
Nurix Therapeutics, Inc.2026-05-15To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.ForAGAINST — 16 of 28 Fidelity fundsFor—
uniQure N.V.2026-06-10Resolution to adopt the amendment to the Articles of Association to reflect Dutch large company regime.ForAGAINST — 10 of 16 Fidelity fundsForApproved, 74.5% support
Phibro Animal Health Corporation2025-11-04Election of Class III Directors: Jack C. BendheimForWITHHOLD — 13 of 22 Fidelity fundsForElected, 96.8% support
Stoke Therapeutics, Inc.2026-06-03Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Julie Anne SmithForWITHHOLD — 14 of 27 Fidelity fundsForPassed (calculated), 86.9% support
UroGen Pharma Ltd.2026-06-22To approve the amendment and restatement of the Articles of Association of the Company to, among other things, tie eligibility for shareholder proposals to the requirements under the Israeli Companies Law.ForAGAINST — 5 of 9 Fidelity fundsForApproved, 68.2% support

Download all 122 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 98.7% of this fund’s 2,820 such votes could be given a sector; the other 38 (1.3%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care2,502431.7%
Industrials12921.6%
Technology6700.0%
Consumer Discretionary5511.8%
Consumer Staples2114.8%
Finance800.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections1,8569
Say-on-Pay3520
Audit-related3370
Compensation1452
Corporate Governance9526
Capital Structure410
Extraordinary Transactions180
Shareholder Rights and Defenses101
Other Social Issues55
Environment or Climate33

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Eli Lilly and CompanyMay 4, 2026$513M102
Johnson & JohnsonApril 23, 2026$303M151
AbbVie Inc.May 8, 2026$234M81
UnitedHealth Group IncorporatedJune 1, 2026$168M121
Merck & Co., Inc.May 26, 2026$162M183
Thermo Fisher Scientific Inc.May 20, 2026$117M130
Amgen Inc.May 19, 2026$112M151
Gilead Sciences, Inc.April 30, 2026$93M153

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalAgainstFor
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalAgainstFor
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalAgainstFor
June 1, 2026UnitedHealth Group IncorporatedIf properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 23, 2026Pfizer Inc.Adopt an Independent Chair Policy Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalAgainstFor

Contested meetings

Meetings with a proxy contest or competing nominees (3 in 2025-2026), and how the fund voted the items on its ballot.

Search this fund’s votes by company

2,863 ballot items at 347 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Fidelity MSCI Health Care Index ETF (FHLC) voted at 347 shareholder meetings of 333 companies, on 2,863 ballot items in all. Where management made a recommendation, the fund followed it on 98.3% of the items and voted against it 47 times. Its most frequent area of disagreement was corporate governance (26 of its votes against management). It voted on 47 shareholder proposals. It voted FOR the board's own proposals more often than Fidelity's funds as a whole (95.8% against 94.1%). It voted differently from most Fidelity funds on 122 items. 3 of its meetings were contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Fidelity’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.